$CBIS - Cannabis Science, Inc. Mega DD http:/
Post# of 144482
Posted On: 05/21/2014 6:09:11 PM
$CBIS - Cannabis Science, Inc. Mega DD
CBIS Company Description
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
CBIS Products and Services
Research & Development Overview
Our products, broadly described, are medical cannabinoid products developed from one or more of the cannabinoid compounds found in the cannabis plant.
Cannabis sativa is one of the most widely used plants for both recreational and medicinal purposes. To date a total of 525 natural constituents covering several chemical classes have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, tetrahydrocannabinol commonly referred to as THC.
The most common natural plant cannabinoids (phytocannabinoids) are: THC, cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). Several of the identified cannabinoids are both chemically and pharmacologically poorly characterized; however, the pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis.
Cannabinoids were first discovered in the 1940s, when CBD and CBN were identified. THC was not identified until 1964, but by that time cannabinoids had been removed from the pharmacopeiae of most countries, making further research on the plant difficult.
There are three general types of cannabinoids:
1. Phytocannabinoids, that occur uniquely in the cannabis plant.
2. Endogenous cannabinoids produced naturally in many animal species including humans.
3. Synthetic cannabinoids compounds produced in a laboratory. Forms of synthetic THC are available by prescription in a number of countries, including the US. In the US, marketed as Marinol®.
Phytocannabinoids, also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids, are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin that is produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.
Cannabinoid receptors in the human body were not discovered until 1988. CB1 receptors are found throughout the body and are the most prevalent neurotransmitter system in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems.
CB2 receptors are found most exclusively in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis. CB2 receptors appear in any tissue when there is pathology.
The endocannabinoid system refers to a group of neuromodulators and receptors involved in a variety of physiological processes including appetite, pain sensation, mood, and memory. The system is named for endocannabinoids, the endogenous lipids that bind cannabinoid receptors.
Science increasingly recognizes the role that endo-cannabinoids play in major life functions in the human body. Cannabinoids act as a bio regulatory mechanism, which explains why they have been recommended as a treatment for many diseases and ailments in anecdotal reports and scientific literature. Common prescribed ailments include: Pain, arthritic conditions, migraine headaches, anxiety, epileptic seizures, insomnia, loss of appetite, GERD (chronic heartburn), nausea, glaucoma, AIDS wasting syndrome, depression, bipolar disorder (particularly depression-manic-normal), multiple sclerosis, menstrual cramps, Parkinson's, trigeminal neuralgia (tic douloureux), high blood pressure, irritable bowel syndrome, and bladder incontinence.
Pipeline - annabis Science's focus is HIV/AIDS (CS-TAT1-I) and Cancer (CS-S/BCC-1)
CS-TATI-1
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2).
Cannabis Science's development of CS-TATI-1 will be targeted to both newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1s, PO1s and SBIRs which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
Our product is a whole plant extract, formulated for topical administration as a Phase I product, then to be potentially investigated as an oral administration for systemic delivery.
CS-S/BCC-1
Since 2011, we have seen apparent success in 4 skin cancer patients who have self-administered CS-S/BCC-1 –cannabinoid based extracts topically to their basal and squamous cell carcinomas. These patients have experienced shrinking and apparent eradication of their skin cancer lesions, backed by positive reports from their doctors. With these results, Cannabis Science is confident it can begin programs for over the counter (OTC) and prescription drug markets. The company is consulting with a team of FDA specialists to plan for a pre-IND meeting with the agency with the goal of creating a road map leading to an IND application.
CBIS Key Company Management
Dr. Robert Melamede, Ph.D. - President and Director
Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabinoids, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Scientific Advisory Board of Americans for Safe Access, the Unconventional Foundation for Autism, The World Aids Institute, Board Tim Brown Foundation (The Berlin Patient), Phoenix Tears Foundation, and regularly consults with professional and lay persons around the world regarding cannabis and health issues. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.
Dr. Dorothy Bray, Ph.D. - Chief Executive Officer and Director
Dr. Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline. Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
http://www.cannabisscience.com/index.php/our-...management
CBIS Contact Info
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
http://www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
561.420.4824
facebook: https://www.facebook.com/cbisinc
Follow Cannabis Science on Twitter @CannabisScienc1
CBIS SEC Filings
http://www.otcmarkets.com/stock/CBIS/filings
CBIS Headlines
http://finance.yahoo.com/q/h?s=CBIS+Headlines
Investigate more about CBIS @ http://www.otcmarkets.com/stock/CBIS/quote for more due diligence.
CBIS Company Description
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
CBIS Products and Services
Research & Development Overview
Our products, broadly described, are medical cannabinoid products developed from one or more of the cannabinoid compounds found in the cannabis plant.
Cannabis sativa is one of the most widely used plants for both recreational and medicinal purposes. To date a total of 525 natural constituents covering several chemical classes have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, tetrahydrocannabinol commonly referred to as THC.
The most common natural plant cannabinoids (phytocannabinoids) are: THC, cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). Several of the identified cannabinoids are both chemically and pharmacologically poorly characterized; however, the pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis.
Cannabinoids were first discovered in the 1940s, when CBD and CBN were identified. THC was not identified until 1964, but by that time cannabinoids had been removed from the pharmacopeiae of most countries, making further research on the plant difficult.
There are three general types of cannabinoids:
1. Phytocannabinoids, that occur uniquely in the cannabis plant.
2. Endogenous cannabinoids produced naturally in many animal species including humans.
3. Synthetic cannabinoids compounds produced in a laboratory. Forms of synthetic THC are available by prescription in a number of countries, including the US. In the US, marketed as Marinol®.
Phytocannabinoids, also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids, are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin that is produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.
Cannabinoid receptors in the human body were not discovered until 1988. CB1 receptors are found throughout the body and are the most prevalent neurotransmitter system in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems.
CB2 receptors are found most exclusively in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis. CB2 receptors appear in any tissue when there is pathology.
The endocannabinoid system refers to a group of neuromodulators and receptors involved in a variety of physiological processes including appetite, pain sensation, mood, and memory. The system is named for endocannabinoids, the endogenous lipids that bind cannabinoid receptors.
Science increasingly recognizes the role that endo-cannabinoids play in major life functions in the human body. Cannabinoids act as a bio regulatory mechanism, which explains why they have been recommended as a treatment for many diseases and ailments in anecdotal reports and scientific literature. Common prescribed ailments include: Pain, arthritic conditions, migraine headaches, anxiety, epileptic seizures, insomnia, loss of appetite, GERD (chronic heartburn), nausea, glaucoma, AIDS wasting syndrome, depression, bipolar disorder (particularly depression-manic-normal), multiple sclerosis, menstrual cramps, Parkinson's, trigeminal neuralgia (tic douloureux), high blood pressure, irritable bowel syndrome, and bladder incontinence.
Pipeline - annabis Science's focus is HIV/AIDS (CS-TAT1-I) and Cancer (CS-S/BCC-1)
CS-TATI-1
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2).
Cannabis Science's development of CS-TATI-1 will be targeted to both newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1s, PO1s and SBIRs which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
Our product is a whole plant extract, formulated for topical administration as a Phase I product, then to be potentially investigated as an oral administration for systemic delivery.
CS-S/BCC-1
Since 2011, we have seen apparent success in 4 skin cancer patients who have self-administered CS-S/BCC-1 –cannabinoid based extracts topically to their basal and squamous cell carcinomas. These patients have experienced shrinking and apparent eradication of their skin cancer lesions, backed by positive reports from their doctors. With these results, Cannabis Science is confident it can begin programs for over the counter (OTC) and prescription drug markets. The company is consulting with a team of FDA specialists to plan for a pre-IND meeting with the agency with the goal of creating a road map leading to an IND application.
CBIS Key Company Management
Dr. Robert Melamede, Ph.D. - President and Director
Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabinoids, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Scientific Advisory Board of Americans for Safe Access, the Unconventional Foundation for Autism, The World Aids Institute, Board Tim Brown Foundation (The Berlin Patient), Phoenix Tears Foundation, and regularly consults with professional and lay persons around the world regarding cannabis and health issues. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.
Dr. Dorothy Bray, Ph.D. - Chief Executive Officer and Director
Dr. Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline. Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
http://www.cannabisscience.com/index.php/our-...management
CBIS Contact Info
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
http://www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
561.420.4824
facebook: https://www.facebook.com/cbisinc
Follow Cannabis Science on Twitter @CannabisScienc1
CBIS SEC Filings
http://www.otcmarkets.com/stock/CBIS/filings
CBIS Headlines
http://finance.yahoo.com/q/h?s=CBIS+Headlines
Investigate more about CBIS @ http://www.otcmarkets.com/stock/CBIS/quote for more due diligence.
(0)
(0)Scroll down for more posts ▼